Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098563 · ClinicalTrials.gov registry record · Phase 2
Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03098563: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03098563 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03098563, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This research is being done to evaluate whether combining medications that are FDA approved, but have not yet been approved for combination treatment, can be effective in reducing pain.
Interventions
- DRUG Blinded study medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03098563
The ClinicalTrials.gov registry entry for NCT03098563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blinded study medication is the first listed.
NCT03098563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03098563 about?
NCT03098563 is a clinical study titled "Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis". This research is being done to evaluate whether combining medications that are FDA approved, but have not yet been approved for combination treatment, can be effective in reducing pain.
What is the current status of trial NCT03098563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2017-11-01. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT03098563?
The interventions under investigation include: Blinded study medication (DRUG).
Who is sponsoring clinical trial NCT03098563?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.